Nakamoto, Shogo
Kajiwara, Yukiko
Taniguchi, Kohei
Hida, Akira I.
Miyoshi, Yuichiro
Kin, Takanori
Yamamoto, Mari
Takabatake, Daisuke
Kubo, Shinichiro
Hikino, Hajime
Ogasawara, Yutaka
Ikeda, Masahiko
Doihara, Hiroyoshi
Shien, Tadahiko
Taira, Naruto
Iwamoto, Takayuki http://orcid.org/0000-0001-5835-5160
Toyooka, Shinichi
Article History
Received: 14 April 2024
Accepted: 5 June 2024
First Online: 18 June 2024
Declarations
:
: SN: Lecture fee: Daiichi-Sankyo, Eisai and Chugai; AH received honoraria from Daiichi-Sankyo, Pfizer, Chugai and is a member of the Advisory Board of Daiichi-Sankyo, Exact Science; Research grant: Visiopharm, MI: Research grant: Lilly, Honoraria: Daiichi-Sankyo, Lilly, Pfizer, Ezai, Kyowa Kirin, Astra Zeneca, Taiho, Celltrion Healthcare Japan, MSD, Tsumura, Nihon Mediphysics, Exact Science, Chugai, Nihon Kayaku; Advisory Board: Daiichi-Sankyo; Manuscript fee: Pfizer, Chugai, Medic Media; TI received a research grant from Pfizer. The other authors declare no conflicts of interest associated with this manuscript.
: Informed consent was obtained from all individual participants included in the study. All authors consent to the publication of this manuscript. The patient informed consent also included a section on consenting to the publication of the patients’ anonymized data.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study received an approval from the Ethics Committee of Okayama University Hospital (1909-032, October, 4 2019) and the respective institution, and each participant provided written informed consent.